Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
51
Recruiting, industry sponsors, Psychiatry, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed532
51 trials
Showing 1 to 25, recently updated first.
- A Study of Brenipatide in Participants With Major Depressive DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07928245 · 330 participants (planned) · Start Nov 10, 2026 · Primary completion May 2028
Drug: Brenipatide; Placebo · For: Major Depressive Disorder
Sites: Chino, California; Fountain Valley, California; Montclair, California · 76 sites in all
- A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07772531 · 200 participants (planned) · Start Oct 30, 2026 · Primary completion Nov 6, 2028
Drug: BMS-986511; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 24 sites in all
- A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07755410 · 312 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 2027
Drug: ALKS 7290; Placebo · For: Attention Deficit Disorder With Hyperactivity (ADHD)
Sites: Little Rock, Arkansas; Chino, California; Clermont, Florida · 28 sites in all
- A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07901179 · 180 participants (planned) · Start Nov 9, 2026 · Primary completion Jan 2028
Drug: ALKS 7290 Dose; Placebo · For: Major Depressive Disorder (MDD)
Sites: Jacksonville, Florida; North Canton, Ohio
- Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderPivotal-lookingRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT07226661 · 230 participants (planned) · Start Jan 19, 2026 · Primary completion Dec 31, 2026
Drug: SPN-821 2400 mg; Placebo · For: Major Depressive Disorder (MDD)
Sites: Birmingham, Alabama; Phoenix, Arizona; Rogers, Arkansas · 40 sites in all
- Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderPivotal-lookingRecruiting
COMPASS PathwaysIndustry
NCT07570654 · 300 participants (planned) · Start Sep 14, 2026 · Primary completion Nov 2028
Drug: COMP360 psilocybin · For: PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms and 1 more
Sites: Tucson, Arizona; Irvine, California; Los Angeles, California · 20 sites in all
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPivotal-lookingRecruiting
MapLight TherapeuticsIndustry
NCT06887192 · 300 participants (planned) · Start Aug 15, 2025 · Primary completion Dec 2027
Drug: ML-007C-MA; Placebo · For: Psychosis Associated With Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 69 sites in all
- A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)Pivotal-lookingRecruiting
Seaport TherapeuticsIndustry
NCT07065240 · 360 participants (planned) · Start Jun 19, 2025 · Primary completion Mar 2027
Drug: SPT-300; Placebo · For: Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress
Sites: Chino, California; Garden Grove, California; Glendale, California · 62 sites in all
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07002034 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: RE104 for Injection · For: Adjustment Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 33 sites in all
- ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponsePivotal-lookingRecruiting
ACADIA Pharmaceuticals Inc.Industry
NCT07284667 · 153 participants (planned) · Start Nov 14, 2025 · Primary completion Aug 2027
Drug: ACP-211; Placebo · For: Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant
Sites: Birmingham, Alabama; Chino, California; Glendale, California · 28 sites in all
- A Study of Brenipatide in Participants With Opioid Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07420283 · 465 participants (planned) · Start Feb 13, 2026 · Primary completion Mar 2028
Drug: Brenipatide; Placebo and 1 more · For: Opioid Use Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Fountain Valley, California · 68 sites in all
- A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07286175 · 400 participants (planned) · Start Nov 24, 2025 · Primary completion Nov 2027
Drug: Brenipatide; Placebo · For: Bipolar Disorder
Sites: Orange, California; New Haven, Connecticut; Hialeah, Florida · 87 sites in all
- Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06480383 · 705 participants (planned) · Start Aug 5, 2024 · Primary completion Mar 16, 2027
Drug: ITI-1284 10 mg; ITI-1284 20 mg and 1 more · For: Generalized Anxiety Disorder
Sites: Glendale, California; Imperial, California; Lemon Grove, California · 59 sites in all
- Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06701903 · 570 participants (planned) · Start Nov 21, 2024 · Primary completion Oct 14, 2027
Drug: ITI-1284 10 mg; ITI-1284 20 mg and 1 more · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Little Rock, Arkansas; Rogers, Arkansas · 51 sites in all
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06540833 · 370 participants (planned) · Start Aug 15, 2024 · Primary completion Sep 30, 2028
Drug: ITI-1284; Placebo · For: Psychotic Disorders; Alzheimer Disease
Sites: Anaheim, California; Los Alamitos, California; Newport Beach, California · 71 sites in all
- A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Tonix Pharmaceuticals, Inc.Industry
NCT07621237 · 360 participants (planned) · Start Jun 25, 2026 · Primary completion Feb 2028
Drug: TNX-102 SL; Placebo sublingual tablet · For: Major Depressive Episode (MDE); Major Depressive Disorder (MDD); Depression
Sites: Phoenix, Arizona; Buena Park, California; Chino, California · 27 sites in all
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruiting
TG Therapeutics, Inc.Industry
NCT07680946 · 60 participants (planned) · Start Jul 27, 2026 · Primary completion Dec 12, 2028
Drug: Ublituximab · For: Schizophrenia
Sites: Little Rock, Arkansas; Richardson, Texas
Psyence Australia Pty LtdIndustry
NCT07072728 · 87 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 30, 2027
Drug: Psilocybin therapy · For: Adjustment Disorder; Adjustment Disorder With Anxious Mood; Cancer and 8 more
Sites: Abbotsford, Australia; Melbourne, Australia; Northcote, Australia · 5 sites in all
- ALTO-207 in Adults With Treatment-resistant Depression (TRD)Pivotal-lookingRecruiting
Alto NeuroscienceIndustry
NCT07553637 · 178 participants (planned) · Start May 20, 2026 · Primary completion Nov 2027
Drug: ALTO-207; Placebo · For: Treatment-resistant Depression (TRD)
Sites: Dothan, Alabama; Phoenix, Arizona; Chino, California · 63 sites in all
- Study of ALTO-300 in MDDPivotal-lookingRecruiting
Alto NeuroscienceIndustry
NCT05922878 · 325 participants (planned) · Start Jun 8, 2023 · Primary completion Dec 2026
Drug: ALTO-300; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Yuma, Arizona; Rogers, Arkansas · 75 sites in all
- Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsPivotal-lookingRecruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT06931080 · 630 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 2027
Drug: EB-1020 (Centanafadine) 164.4 mg; EB-1020 (Centanafadine) 328.8 mg and 1 more · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Tokyo, Japan
Adneuris Therapeutics, Inc.Industry
NCT07874620 · 45 participants (planned) · Start Oct 2026 · Primary completion Mar 2027
Drug: Cebranopadol; Cebranopadol and 1 more · For: Chronic Pain; Pain; Opioid Withdrawal (Disorder) and 1 more
Sites: North Canton, Ohio; Houston, Texas
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS TrialPivotal-lookingRecruiting
NeuroRx, Inc.Industry
NCT07227103 · 240 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Drug: NRX-101; Oral Placebo · For: Treatment Resistant Depression; Treatment Resistant Depression (TRD)
Sites: Sarasota, Florida; West Palm Beach, Florida; Belmont, Massachusetts
- Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDDPivotal-lookingRecruiting
Vigonvita Life SciencesIndustry
NCT06828887 · 400 participants (planned) · Start Apr 3, 2025 · Primary completion Sep 1, 2027
Drug: LV232 40mg; LV232 60mg and 2 more · For: MDD
Sites: Shanghai, China
MapLight TherapeuticsIndustry
NCT07459647 · 500 participants (planned) · Start Mar 31, 2026 · Primary completion Feb 2030
Drug: ML-007C-MA · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Bellflower, California · 45 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.